82 related articles for article (PubMed ID: 18312292)
1. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.
Brower ET; Bacha UM; Kawasaki Y; Freire E
Chem Biol Drug Des; 2008 Apr; 71(4):298-305. PubMed ID: 18312292
[TBL] [Abstract][Full Text] [Related]
2. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.
Velazquez-Campoy A; Todd MJ; Vega S; Freire E
Proc Natl Acad Sci U S A; 2001 May; 98(11):6062-7. PubMed ID: 11353856
[TBL] [Abstract][Full Text] [Related]
3. In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.
Gonzalez LM; Brindeiro RM; Tarin M; Calazans A; Soares MA; Cassol S; Tanuri A
Antimicrob Agents Chemother; 2003 Sep; 47(9):2817-22. PubMed ID: 12936979
[TBL] [Abstract][Full Text] [Related]
4. Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
Clemente JC; Coman RM; Thiaville MM; Janka LK; Jeung JA; Nukoolkarn S; Govindasamy L; Agbandje-McKenna M; McKenna R; Leelamanit W; Goodenow MM; Dunn BM
Biochemistry; 2006 May; 45(17):5468-77. PubMed ID: 16634628
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Protease Dimerization Dynamics Reveals a Transient Druggable Binding Pocket at the Interface.
Pietrucci F; Vargiu AV; Kranjc A
Sci Rep; 2015 Dec; 5():18555. PubMed ID: 26692118
[TBL] [Abstract][Full Text] [Related]
6. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.
Tie Y; Wang YF; Boross PI; Chiu TY; Ghosh AK; Tozser J; Louis JM; Harrison RW; Weber IT
Protein Sci; 2012 Mar; 21(3):339-50. PubMed ID: 22238126
[TBL] [Abstract][Full Text] [Related]
7. Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities.
Manna S; Das K; Santra S; Nosova EV; Zyryanov GV; Halder S
Viruses; 2023 Aug; 15(9):. PubMed ID: 37766233
[TBL] [Abstract][Full Text] [Related]
8. Promising Schiff bases in antiviral drug design and discovery.
Kaushik S; Paliwal SK; Iyer MR; Patil VM
Med Chem Res; 2023; 32(6):1063-1076. PubMed ID: 37305208
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds.
Moranguinho I; Taveira N; Bártolo I
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982978
[TBL] [Abstract][Full Text] [Related]
10. Metal-based complexes against SARS-CoV-2.
Ioannou K; Vlasiou MC
Biometals; 2022 Aug; 35(4):639-652. PubMed ID: 35332435
[TBL] [Abstract][Full Text] [Related]
11. Repurposing of Antimicrobial Agents for Cancer Therapy: What Do We Know?
Pfab C; Schnobrich L; Eldnasoury S; Gessner A; El-Najjar N
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206772
[TBL] [Abstract][Full Text] [Related]
12. Structural Impacts of Drug-Resistance Mutations Appearing in HIV-2 Protease.
Laville P; Petitjean M; Regad L
Molecules; 2021 Jan; 26(3):. PubMed ID: 33503916
[TBL] [Abstract][Full Text] [Related]
13. Biochemical Characterization of Human Retroviral-Like Aspartic Protease 1 (ASPRV1).
Golda M; Mótyán JA; Nagy K; Matúz K; Nagy T; Tőzsér J
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32640672
[TBL] [Abstract][Full Text] [Related]
14. Impacts of drug resistance mutations on the structural asymmetry of the HIV-2 protease.
Laville P; Fartek S; Cerisier N; Flatters D; Petitjean M; Regad L
BMC Mol Cell Biol; 2020 Jun; 21(1):46. PubMed ID: 32576133
[TBL] [Abstract][Full Text] [Related]
15. Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20.
Kneller DW; Agniswamy J; Ghosh AK; Weber IT
Biochem Biophys Res Commun; 2019 Oct; 519(1):61-66. PubMed ID: 31474336
[TBL] [Abstract][Full Text] [Related]
16. Management of Virologic Failure and HIV Drug Resistance.
McCluskey SM; Siedner MJ; Marconi VC
Infect Dis Clin North Am; 2019 Sep; 33(3):707-742. PubMed ID: 31255384
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Reasons for Decrease in Binding Affinity of HIV-2 Against HIV-1 Protease Complex Using Interaction Entropy Under Polarized Force Field.
Cong Y; Li Y; Jin K; Zhong S; Zhang JZH; Li H; Duan L
Front Chem; 2018; 6():380. PubMed ID: 30197882
[TBL] [Abstract][Full Text] [Related]
18.
Smith RA; Wu VH; Zavala CG; Raugi DN; Ba S; Seydi M; Gottlieb GS;
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012774
[TBL] [Abstract][Full Text] [Related]
19. Exploration of the effect of sequence variations located inside the binding pocket of HIV-1 and HIV-2 proteases.
Triki D; Billot T; Visseaux B; Descamps D; Flatters D; Camproux AC; Regad L
Sci Rep; 2018 Apr; 8(1):5789. PubMed ID: 29636521
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
